The "International Right to Know Day" is celebrated around the world by access to information advocates. This year, the European Ombudsman, Emily O'Reilly, wants to look into the question of how transparent scientific data, and more specifically clinical trial data, is for the benefit of patients, doctors, and researchers who need maximum information about the medicines they take, prescribe, and analyse.In June 2014, the EU agreed legislation to make future clinical trial data publicly accessible online as of 2016. However, many open questions remain about access to existing clinical trial data about medicines currently on the market.The discussion takes place in the wider context of the Open Government Partnership, an international platform committed to making governments and public administrations more open, accountable, and responsive to citizens.Speakers• Emily O'Reilly, European Ombudsman• Margrete Auken, MEP, shadow rapporteur, clinical trials regulation• Guido Rasi, Executive Director of the European Medicines Agency• Ben Goldacre, physician, academic, and author of "Bad Pharma"• Richard Bergström, Director General of the European Federation of Pharmaceutical Industries and AssociationsChairFrédéric Simon, publisher and editor, EurActivParticipate in the Twitter debate at #rtkd2014eo